Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens.

Mendes RE, Rhomberg PR, Lister T, Cotroneo N, Rubio A, Flamm RK.

Microb Drug Resist. 2019 Oct 9. doi: 10.1089/mdr.2019.0198. [Epub ahead of print]

PMID:
31596663
2.
3.

Regional Analysis of Telavancin and Comparator Antimicrobial Activity against Multidrug-Resistant Staphylococcus aureus Collected in the United States from 2014 through 2016.

Duncan LR, Smith CJ, Flamm RK, Mendes RE.

J Glob Antimicrob Resist. 2019 Jul 17. pii: S2213-7165(19)30173-0. doi: 10.1016/j.jgar.2019.07.007. [Epub ahead of print]

4.

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017).

Sader HS, Castanheira M, Streit JM, Flamm RK.

Diagn Microbiol Infect Dis. 2019 Jun 11:114850. doi: 10.1016/j.diagmicrobio.2019.06.002. [Epub ahead of print]

PMID:
31296360
5.
6.

In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017.

Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e00840-19. doi: 10.1128/AAC.00840-19. Print 2019 Aug.

PMID:
31182527
7.

Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam.

Belley A, Huband MD, Fedler KA, Watters AA, Flamm RK, Shapiro S, Knechtle P.

J Clin Microbiol. 2019 Jul 26;57(8). pii: e00607-19. doi: 10.1128/JCM.00607-19. Print 2019 Aug.

PMID:
31167844
8.

Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015).

Pfaller MA, Sader HS, Shortridge D, Castanheira M, Flamm RK, Mendes RE.

J Chemother. 2019 Jul;31(4):188-194. doi: 10.1080/1120009X.2019.1609740. Epub 2019 May 13.

PMID:
31079589
9.

Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections.

Shortridge D, Flamm RK.

Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S200-S205. doi: 10.1093/cid/ciz003.

10.

Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms.

Arends SJR, Rhomberg PR, Cotroneo N, Rubio A, Flamm RK, Mendes RE.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02618-18. doi: 10.1128/AAC.02618-18. Print 2019 Jun.

PMID:
30936096
11.

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17).

Carvalhaes CG, Sader HS, Flamm RK, Mendes RE.

J Antimicrob Chemother. 2019 Jul 1;74(7):1928-1933. doi: 10.1093/jac/dkz120.

PMID:
30932152
12.

Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers.

Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02655-18. doi: 10.1128/AAC.02655-18. Print 2019 Jun.

PMID:
30910899
13.

Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997-2016.

Pfaller MA, Cormican M, Flamm RK, Mendes RE, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S54-S62. doi: 10.1093/ofid/ofy344. eCollection 2019 Mar.

14.

Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016).

Sader HS, Mendes RE, Le J, Denys G, Flamm RK, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S14-S23. doi: 10.1093/ofid/ofy263. eCollection 2019 Mar.

15.

Antimicrobial Resistance Surveillance and New Drug Development.

Sader HS, Rhomberg PR, Fuhrmeister AS, Mendes RE, Flamm RK, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S5-S13. doi: 10.1093/ofid/ofy345. eCollection 2019 Mar.

16.

Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves.

Flamm RK, Rhomberg PR, Lindley JM, Sweeney K, Ellis-Grosse EJ, Shortridge D.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02549-18. doi: 10.1128/AAC.02549-18. Print 2019 May.

PMID:
30858207
18.
19.

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.

Huband MD, Pfaller MA, Shortridge D, Flamm RK.

J Glob Antimicrob Resist. 2019 Feb 27;19:56-63. doi: 10.1016/j.jgar.2019.02.017. [Epub ahead of print]

PMID:
30825698
20.

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).

Pfaller MA, Flamm RK, Duncan LR, Shortridge D, Smart JI, Hamed KA, Mendes RE, Sader HS.

Diagn Microbiol Infect Dis. 2019 Jul;94(3):304-313. doi: 10.1016/j.diagmicrobio.2019.01.015. Epub 2019 Jan 26.

PMID:
30808530
21.

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.

Sader HS, Mendes RE, Pfaller MA, Flamm RK.

J Antimicrob Chemother. 2019 May 1;74(5):1306-1310. doi: 10.1093/jac/dkz006.

PMID:
30753485
22.

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.

Shortridge D, Duncan LR, Pfaller MA, Flamm RK.

Int J Antimicrob Agents. 2019 May;53(5):637-643. doi: 10.1016/j.ijantimicag.2019.01.015. Epub 2019 Feb 1.

PMID:
30716448
23.

In Vitro Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015) in the United States.

Pfaller MA, Sader HS, Rhomberg PR, Flamm RK, Mendes RE.

Microb Drug Resist. 2019 Jul/Aug;25(6):938-943. doi: 10.1089/mdr.2018.0410. Epub 2019 Jan 29.

PMID:
30694735
24.

Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.

Mendes RE, Paukner S, Doyle TB, Gelone SP, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02158-18. doi: 10.1128/AAC.02158-18. Print 2019 Apr.

25.

Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).

Paukner S, Gelone SP, Arends SJR, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02161-18. doi: 10.1128/AAC.02161-18. Print 2019 Apr.

26.

Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.

Carvalhaes CG, Castanheira M, Sader HS, Flamm RK, Shortridge D.

Diagn Microbiol Infect Dis. 2019 May;94(1):93-102. doi: 10.1016/j.diagmicrobio.2018.11.021. Epub 2018 Nov 30.

PMID:
30642717
27.

Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016).

Carvalhaes CG, Huband MD, Reinhart HH, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02262-18. doi: 10.1128/AAC.02262-18. Print 2019 Mar.

28.

In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016).

Duncan LR, Flamm RK, Sader HS, Mendes RE.

Diagn Microbiol Infect Dis. 2019 Feb;93(2):167-170. doi: 10.1016/j.diagmicrobio.2018.09.011. Epub 2018 Oct 2.

29.

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016.

Pfaller MA, Flamm RK, Mendes RE, Streit JM, Smart JI, Hamed KA, Duncan LR, Sader HS.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01566-18. doi: 10.1128/AAC.01566-18. Print 2019 Jan.

30.

Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America.

Sader HS, Flamm RK, Streit JM, Carvalhaes CG, Mendes RE.

Int J Infect Dis. 2018 Dec;77:82-86. doi: 10.1016/j.ijid.2018.10.004. Epub 2018 Oct 10.

31.

Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates.

Sader HS, Rhomberg PR, Doyle TB, Flamm RK, Mendes RE.

J Clin Microbiol. 2018 Nov 27;56(12). pii: e00777-18. doi: 10.1128/JCM.00777-18. Print 2018 Dec.

32.

Activity of fosfomycin when tested against US contemporary bacterial isolates.

Flamm RK, Rhomberg PR, Watters AA, Sweeney K, Ellis-Grosse EJ, Shortridge D.

Diagn Microbiol Infect Dis. 2019 Feb;93(2):143-146. doi: 10.1016/j.diagmicrobio.2018.08.010. Epub 2018 Aug 28.

PMID:
30236530
33.

Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.

Sader HS, Flamm RK, Carvalhaes CG, Castanheira M.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01587-18. doi: 10.1128/AAC.01587-18. Print 2018 Dec.

34.
35.

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).

Sader HS, Castanheira M, Mendes RE, Flamm RK.

J Antimicrob Chemother. 2018 Nov 1;73(11):3053-3059. doi: 10.1093/jac/dky279.

PMID:
30060117
36.

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.

Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.

J Antimicrob Chemother. 2018 Oct 1;73(10):2748-2756. doi: 10.1093/jac/dky235.

PMID:
29982565
37.

Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.

Sader HS, Flamm RK, Dale GE, Rhomberg PR, Castanheira M.

J Antimicrob Chemother. 2018 Sep 1;73(9):2400-2404. doi: 10.1093/jac/dky227.

PMID:
29901750
39.

Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program.

Deshpande LM, Castanheira M, Flamm RK, Mendes RE.

J Antimicrob Chemother. 2018 Sep 1;73(9):2314-2322. doi: 10.1093/jac/dky188.

PMID:
29878213
40.

In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes.

Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00313-18. doi: 10.1128/AAC.00313-18. Print 2018 Aug.

41.

Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone.

Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D, Jones RN.

J Clin Microbiol. 2018 Jul 26;56(8). pii: e00339-18. doi: 10.1128/JCM.00339-18. Print 2018 Aug.

42.
43.

Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.

Sader HS, Dale GE, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00311-18. doi: 10.1128/AAC.00311-18. Print 2018 Jul.

44.

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries.

Mendes RE, Deshpande L, Streit JM, Sader HS, Castanheira M, Hogan PA, Flamm RK.

J Antimicrob Chemother. 2018 Jul 1;73(7):1880-1887. doi: 10.1093/jac/dky099.

PMID:
29659858
45.

Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.

Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK.

Int J Antimicrob Agents. 2018 Aug;52(2):287-292. doi: 10.1016/j.ijantimicag.2018.04.001. Epub 2018 Apr 11.

PMID:
29654893
46.

Erratum for Drusano et al., "Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia".

Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e00198-18. doi: 10.1128/AAC.00198-18. Print 2018 Apr. No abstract available.

47.

Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014).

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):179-183. doi: 10.1016/j.diagmicrobio.2018.01.019. Epub 2018 Feb 24.

PMID:
29571839
48.

Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.

Pfaller MA, Sader HS, Flamm RK, Castanheira M, Mendes RE.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):199-204. doi: 10.1016/j.diagmicrobio.2018.01.029. Epub 2018 Feb 3.

PMID:
29567128
49.

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.

Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK, Jones RN.

J Clin Microbiol. 2018 May 25;56(6). pii: e01960-17. doi: 10.1128/JCM.01960-17. Print 2018 Jun.

50.

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.

Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M.

Int J Antimicrob Agents. 2018 Aug;52(2):144-150. doi: 10.1016/j.ijantimicag.2018.02.021. Epub 2018 Mar 3.

PMID:
29510189

Supplemental Content

Loading ...
Support Center